patients with diabetes, HRQoL was lower across all health dimensions measured by the EQ-5D-5L: dimension; mobility, and self-care. Individualized therapeutic manage-
ment programs could be considered in order to improve the HRQoL of CAD patients with diabetes.

PCV137
TRANSLATION AND CULTURAL ADAPTATION OF PATIENT PERCEPTION OF ARRHYTHMIA QUESTIONNAIRE IN POLAND
Farkowski M.M., Skroumpelos A., Woloszczak L., Wood K.A., Szwed H1
1Institute of Cardiology, Warsaw, Poland, 2Department of Experimental and Clinical Pharmacology, Medical University of Warsaw; Warsaw, Poland, 3Duke University School of Nursing, Durham, NC, USA

OBJECTIVES: Patient Perception of Arrhythmia Questionnaire (PPAQ) is a disease-specific questionnaire designed to measure symptoms and health-related quality of life in patients suffering from a group of arrhythmias collectively called supraven-
tricular tachycardia. There is no validated Polish translation of PPAQ with which hinders research in this area with Polish arrhythmia patients. The aim of this study was to conduct initial content validity testing through translation and cultural adaptation of the English language version of the PPAQ to the Polish lan-
guage. METHODS: The whole process was conducted according to ICFBIS Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PROM) Measures published in 2005. RESULTS: In 2011, the PPAQ was translated into Polish and cultural adaptation was performed on 20 patients with SVT (12 male, age 54.9 ± 17.4). Issues concerning close meanings of symptom names and language-dependent gender-related distinctions were identified. The former was solved by cooperation with experts in arrhythmia and latter by incor-
porating new phrases and terms. Content validity was well accepted by patients during this translation and initial content validity testing. Issues arisen during the translation process may recur in other translations and be resolved in similar manners.

PCV138
HEART-RELATED QUALITY OF LIFE IN PATIENTS ALONG FIRST YEAR: POSTSTROKE IN SPAIN
Álvarez Sabin J1, Masjuan J1, Torres C2, Mat J1, Olivera J1, González-Roja N3
1Hospital Vall D’Hebron, Barcelona, Spain, 2Hospital Ramón y Cajal, Madrid, Spain, 3Pharmacoeconomics & Outcomes Research Institute, Madrid, Spain, 4Hospital Alcalá de Henares, Madrid, Spain, 5Mondragon, Spain, 6Cástilla-La Mancha University, Toledo, Spain, 7Boehringer Ingelheim, Sant Cugat del Vallés (Barcelona), Spain

OBJECTIVES: At atrial fibrillation (AF) 5-folds stroke risk, which results in death or disa-
Bility in 80% of patients and with one-year mortality approaches 50%. The objective of the present study was to analyze the heart-related quality of life (HRQoL) one year post-stroke in patients with or without AF and the burden of caregivers. METHODS: We performed an observational, multicenter, naturalistic and prospective study that included 16 stroke units from different Spanish regions. We used EQ-5D and VAS to test patients HRQoL and Zart Burden Inventory to estimate the caregiver burden. We collected information at hospital entry for patients, 3 and 12 months post stroke both for patients and carers through direct physician interviews. RESULTS: A total of 321 stroke patients were recruited, 160 with and 161 without AF. EQ-5D was completed by 274 patients - 127 with AF and 147 without AF - and VAS by 249 - 113 and 136 without AF - The average utility scores of EQ-5D were 0.57, 0.62 and 0.65. We found a statistically significant difference between AF and non-AF obtained at hospital entry (p < 0.029) and 12 months post-stroke (p = 0.023). There were no statistically significant differences obtained at 3rd visit (p = 0.289). If we took into consideration the age of patients, the absence or presence of AF in EQ-5D scores, lost its signifi-
cance (p = 0.099). VAS average scores were 45.81, 44.15 and 45.74. VAS results showed non-statistically significant differences neither by AF presence (p = 0.396) nor time (p = 0.613). Caregiver burden was higher in AF than non-AF patients (46.47 vs 40.93 2nd visit and 45.29 vs 38.73 3rd visit) and the difference was statistically significant (p = 0.007 and p = 0.002). CONCLUSIONS: Stroke has a deep impact on patients HRQoL with no impact in caregivers. In the same line, caregivers also support an important burden related to stroke and specially in AF patients.

PCV140
TREATMENT SATISFACTION IN PATIENTS WITH ATRIAL FIBRILLATION ON NEW ORAL ANTICOAGULANTS AS MEASURED WITH PACT-Q2: PREFER IN AF REGISTRY
Badjic K1, Reimz F2, Volz F2, Leverkus F3, Volz P2, Dörrie R2, Schilling R3, Schwertfeger M2, Zamaro J1, Kirchhof C
1Steinbeis-University Berlin-Berlin GmbH, Berlin, Germany, 2Daichi Sankyo Europe, Munich, Germany, 3Pfizer Deutschland GmbH, Munich, Germany

OBJECTIVES: In order to identify differences in the length of hospital stay for patients with atrial fibrillation (AF) with and without oral anticoagulation (OA). Longer stays of patients could lead to an economical burden for the hospital because of the Diagnosis Related Groups (DRG) system in Germany and the compensa-
tion based lump sum. METHODS: We conducted a cross-sectional study using an electronic DRG benchmarking database. This database contains DRG data from 208 hospitals in Germany with over 2,800,000 inpatient cases per year. In total, 10,912,932 cases from the year 2010 to 2012 were analyzed. 661,845 cases fulfilled the inclusion criteria and were analyzed according the statistical analy-
sis plan including matched pair analyses. RESULTS: Cases with AF and surgical intervention compared to cases without AF and with surgical intervention have a significantly longer pre-operation length of stay (+0.74 days) and a significantly longer hospital stay (+1.5 days). Furthermore cases with chronic AF (~AF+OA) have a significantly longer total length of stay in the hospital (+0.86 days). For the cases with AF and bleeding vs. cases without bleeding, there is no significant difference in the total length of stay, but there is a significantly longer stay of 0.82 days compared to the average length of stay in the DRG-catalogue. CONCLUSIONS: Patients with AF and with or without OA could be an economic burden for the hospital, because the increased length of stay in hospital leads to higher costs whereas the existing compensation diagnosis-based lump sum is not affected by increased treatment days. The new oral anticoagulants could lead to shorter stays of patients with AF by shortening the bridging doses. Statistical analysis showed no impact on NOACs. 5.2% on antiplatelets (AF) and 11.0% on VKA+AF combinations. In the group of patients with ≥ 100 mg aspirin, the score was significantly higher in the NOAC group (66.6 ± 16.6) compared to the VKA group (63.2 ± 15.9), AF (63.7 ± 16.8), or VKA + AF groups (62.8 ± 15.0), respectively. CONCLUSIONS: Overall, patients on current anticoagulation achieve relatively high values on the convenience scale, but moderate values on the satisfaction scale. While differences in group size and patient characteristics need to be taken into account, patients on NOACs compared to patients on VKAs tend to rate their convenience and treat-
manship satisfaction higher.

PCV141
CHRONIC PATIENTS’ WILINGNESS TO PAY FOR AN ALTERNATIVE DRUG WITH INNOVATIVE CHARACTERISTICS
Madsen L., Skrzynkowski A2, Lassen P.E., Reimitz P.E., Hjortdal J.P., KisselTH, Brüggenjürgen B.
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece

OBJECTIVES: Aim of the study was to investigate whether chronic patients are willing to pay an extra amount of money in order to switch to another drug that it is either on patent, more effective or simpler in dose. METHODS: A cross-sectional study was conducted among 1600 chronic patients suffering from diabetes, hyper-
tension, COPD and Alzheimer. Logistic regression analysis was carried out to explore the factors that influence patients’ decision on willingness to pay (WTP) for an alternative drug with innovative characteristics. RESULTS: Of the 1600 patients approached, 1594 responded to the survey (99.6%). A total of 40% stated that they would be willing to pay more for a patent drug, 0.74% for a more effective drug and 37.5% for a simpler in dose drug. The average additional amount per month that they would be willing to spend was estimated at 23.61 for a patent drug, 24.14 for a more effective drug and 21.94 € for a simpler in dose drug. No statistically relevant difference of patients’ willingness to pay (WTP) for a patent drug was statistically significant related with the patient’s income (OR, 21.495%; 1.14-3.41) while WTP for a more effective or a simpler in dose drug was positively related with the patient’s income (OR, 25.745%; 1.13-1.39 and OR, 1.1495%; 1.05-1.24 respectively) and educational level (OR, 1.0695%; 1.01-1.13 and OR, 1.0695%; 1.01-1.13, respectively). CONCLUSIONS: Half of chronic patients demonstrate absolute willingness to increase spending for an innovative drug, which highlights the significance they attribute to pharmaceuticals for the management of their condition. The remaining 50% reluctance may be attributed to the extended trust on their current pharmaceutical treatment and to the efforts and money spent in order to control their condition. However, patients with higher socioeconomic status are more likely to express WTP which reflects the economic burden imposed by chronic conditions, and the role of education in shaping patient attitudes.

CARDIOVASCULAR DISORDERS – Health Care Use & Policy Studies

PCV143
EVALUATION OF THE LENGTH OF HOSPITAL STAY FOR PATIENTS WITH ATRIAL FIBRILLATION
Saba, M.1, Mutschewick F., Wilke M., Leverkus F.
Pfizer Deutschland GmbH, Berlin, Germany, Pfizer – Bristol-Myers Squibb GmbH & Co KG, Munich, Germany

OBJECTIVES: The purpose of the study was to investigate whether chronic patients are willing to pay for a patent drug, 57.5% for a more effective drug.